All In Biotech

Drug Trial Radar · NCT06892522

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 602 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

602

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Dec 2035

Study completion Mar 2036

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM. Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of MM. This study is broken into 8 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants in substudies 1-4 will receive escalating doses of etentamig alone or with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R), followed by etentamig at the dose levels established during the escalation phases alone or with DR, Kd and R. Participants in substudies 5-8 will receive up to two doses of ABBV-2001 or at the dose level(s) established during the escalation phases of ABBV-2001 with iberdomide, mezigdomide, pomalidomide or lenalidomide. Around 602 adult participants with MM will be enrolled at approximately 55 sites worldwide In substudies 1-3, participants will receive escalating doses of etentamig as Intravenous (IV) infusions, alone or with DR, R or Kd, followed by SC injections of etentamig at the dose levels established during the escalation phases alone or with DR or K. In substudy 4, participants will receive escalating doses of etentamig as Intravenous (IV) infusions followed by SC injections of etentamig at the dose levels established during the escalation phase with Lenalidomide. In substudies 5-8, participants will receive up to two doses of ABBV-2001 as subcutaneous (SC) injections, with oral iberdomide, mezigdomide, pomalidomide or lenalidomide followed by SC injections of ABBV-2001 at the dose level(s) established during the escalation phases with oral iberdomide, mezigdomide, pomalidomide or lenalidomide. The study duration is approximately 130 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Conditions

  • Multiple Myeloma

Interventions

  • EtentamigDrug

    Intravenous (IV) Infusion

  • LenalidomideDrug

    Oral

  • DexamethasoneDrug

    IV Injection

  • DaratumumabDrug

    Subcutaneous (SC) Injection

  • DexamethasoneDrug

    Oral

  • CarfilzomibDrug

    Intravenous (IV) Infusion

  • MezigdomideDrug

    Oral

  • IberdomideDrug

    Oral

  • ABBV-2001Drug

    Subcutaneous (SC) Injection

  • EtentamigDrug

    Subcutaneous (SC) Injection

  • PomalidomideDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 130 Months
  2. Substudy 1: Dose-Limiting Toxicity (DLT) of Etentamig + Daratumumab and Lenalidomide (DR) in Participants with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)Time frame: Up to Approximately 8 weeks
  3. Substudy 2: DLT of Etentamig Monotherapy as Maintenance in Participants with Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM)Time frame: Up to Approximately 8 Weeks
  4. Substudy 3: DLT of Etentamig +Carfilzomib and Dexamethasone (Kd) Combination in Participants with Relapsed or Refractory Multiple Myeloma (RR MM)Time frame: Up to Approximately 8 Weeks
  5. Substudy 4: DLT of Etentamig plus Lenalidomide when Given as Maintenance in Participants with TE NDMMTime frame: Up to Approximately 8 Weeks
  6. Substudy 5: DLT of ABBV-2001 in Combination with Iberdomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
  7. Substudy 6: DLT of ABBV-2001 in Combination with Mezigdomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
  8. Substudy 7: DLT of ABBV-2001 in Combination with Pomalidomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks
  9. Substudy 8: DLT of ABBV-2001 in Combination with Lenalidomide in Participants with RR MMTime frame: Up to Approximately 8 Weeks

Locations

36 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center /ID# 273132

    Duarte, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911

    Irvine, California · Recruiting

  • University Of California, San Francisco /ID# 271662

    San Francisco, California · Recruiting

  • Colorado Blood Cancer Institute /ID# 273129

    Denver, Colorado · Recruiting

  • Moffitt Cancer Center /ID# 272628

    Tampa, Florida · Recruiting

  • Winship Cancer Institute of Emory University /ID# 274830

    Atlanta, Georgia · Recruiting

  • Mount Sinai - The Tisch Cancer Institute /ID# 272470

    New York, New York · Recruiting

  • Weill Cornell Medical College /ID# 272517

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill /ID# 274667

    Chapel Hill, North Carolina · Recruiting

  • Atrium Health Levine Cancer Institute /ID# 276193

    Charlotte, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Medical Center /ID# 274847

    Winston-Salem, North Carolina · Recruiting

  • Oncology Hematology Care - Blue Ash /ID# 272918

    Cincinnati, Ohio · Recruiting

  • The Ohio State University /ID# 271336

    Columbus, Ohio · Recruiting

  • University of Texas - Southwestern Medical Center /ID# 274360

    Dallas, Texas · Recruiting

  • Huntsman Cancer Institute /ID# 272575

    Salt Lake City, Utah · Recruiting

  • Coffs Harbour Health Campus /ID# 272010

    Coffs Harbour, New South Wales, Australia · Recruiting

  • Port Macquarie Base Hospital /ID# 275925

    Port Macquarie, New South Wales, Australia · Recruiting

  • Westmead Hospital /ID# 271880

    Westmead, New South Wales, Australia · Recruiting

  • Icon Cancer Care - South Brisbane /ID# 271836

    South Brisbane, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital /ID# 272629

    Adelaide, South Australia, Australia · Recruiting

  • St Vincent's Hospital - Melbourne /ID# 276451

    Fitzroy, Victoria, Australia · Recruiting

  • Peter MacCallum Cancer Centre. /ID# 272024

    Melbourne, Victoria, Australia · Recruiting

  • The Perth Blood Institute - West Perth /ID# 272469

    West Perth, Western Australia, Australia · Recruiting

  • Rambam Health Care Campus- Haifa /ID# 271364

    Haifa, Israel · Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 271362

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center. /ID# 271365

    Petah Tikva, Central District, Israel · Recruiting

  • Soroka Medical Center /ID# 271367

    Beersheba, Southern District, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 271366

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Nagoya City University Hospital /ID# 273529

    Nagoya, Aichi-ken, Japan · Recruiting

  • University Hospital Kyoto Prefectural University of Medicine /ID# 275713

    Kyoto, Kyoto, Japan · Recruiting

  • The University of Osaka Hospital /ID# 275791

    Suita-shi, Osaka, Japan · Recruiting

  • Japanese Red Cross Medical Center /ID# 273530

    Shibuya-ku, Tokyo, Japan · Recruiting

  • Oslo Universitetssykehus Ulleval /ID# 277915

    Oslo, Norway · Recruiting

  • University Hospitals Birmingham NHS Foundation Trust /ID# 274620

    Birmingham, United Kingdom · Recruiting

  • University Hospital of Wales /ID# 273446

    Cardiff, United Kingdom · Recruiting

  • Hammersmith Hospital /ID# 274615

    London, England, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.